CD
ORGS

Chapin Davis’s Orgenesis Inc. Common Stock ORGS Stock Holding History

Chapin Davis’s Portfolio ORGS Stock Details ORGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,000
Closed -$12K – 246
2024
Q2 		$12K Hold
2,000
– – ﹤0.01% 227
2024
Q1 		$16.4K Hold
2,000
– – 0.01% 231
2023
Q4 		$10K Hold
2,000
– – ﹤0.01% 215
2023
Q3 		$12.4K Hold
2,000
– – 0.01% 201
2023
Q2 		$27.8K Hold
2,000
– – 0.01% 216
2023
Q1 		$23.6K Hold
2,000
– – 0.01% 222
2022
Q4 		$39K Buy
+2,000
New +$34.1K 0.02% 197

Other funds holding ORGS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Chapin Davis's ORGS Position: Q3 2024 in Review

Chapin Davis sold out of Orgenesis Inc. Common Stock (ORGS) in Q3 2024, closing a stake of 2,000 shares — an estimated $12K sold.

Chapin Davis first reported a position in ORGS in Q4 2022 and held it in 7 quarters. The position peaked at $39K in Q4 2022. 11 funds tracked by Wall St. Rank hold ORGS as of Q3 2024.

  • Chapin Davis reported no remaining Orgenesis Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Chapin Davis sold 2,000 Orgenesis Inc. Common Stock shares in Q3 2024, an estimated $12K.
  • Chapin Davis first reported a position in Orgenesis Inc. Common Stock in Q4 2022 and held it in 7 quarters.
  • Chapin Davis's Orgenesis Inc. Common Stock position peaked at $39K in Q4 2022.
  • 11 funds tracked by Wall St. Rank held Orgenesis Inc. Common Stock as of Q3 2024.

Based on Chapin Davis's 13F filing for Q3 2024, filed 7 Oct 2024.